— Know what they know.
Not Investment Advice

DYN NASDAQ

Dyne Therapeutics, Inc.
1W: -5.0% 1M: -11.7% 3M: +16.7% YTD: -6.1% 1Y: +40.8% 3Y: +30.1% 5Y: -0.6%
$17.37
+0.00 (+0.00%)
 
Weekly Expected Move ±7.8%
$15 $16 $17 $19 $20
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 36 · $2.9B mcap · 131M float · 1.54% daily turnover · Short 77% of daily vol

Balance Sheet Trends

Total Assets
$1.2B +71.7% ▲
5Y CAGR: +27.4%
Total Liabilities
$215M +249.9% ▲
5Y CAGR: +81.3%
Shareholders Equity
$972M +54.3% ▲
5Y CAGR: +23.2%
Cash & Investments
$1.1B +72.9% ▲
5Y CAGR: +26.3%
Total Debt
$20M -15.5% ▼
Net Debt
-$873M -112.2% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$201M$172M$122M$435M$893M
Short-Term Investments$176M$84M$1M$207M$217M
Cash & ST Investments$377M$256M$123M$642M$1.1B
Net Receivables$0$0$0$0$0
Inventory$0$0$0$0$0
Other Current Assets$0$10M$6M$17M$16M
Total Current Assets$382M$266M$129M$659M$1.1B
Property, Plant & Equip.$41M$38M$33M$30M$45M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$2M$2M$2M$2M$16M
Total Non-Current Assets$43M$41M$36M$32M$60M
Total Assets$426M$306M$165M$691M$1.2B
— Liabilities —
Accounts Payable$4M$5M$23M$7M$8M
Short-Term Debt$0$0$0$0$5M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$0$0$0$31M$38M
Total Current Liabilities$29M$28M$51M$42M$51M
Long-Term Debt$0$0$0$0$15M
Other Non-Current Liab.$0$0$0$0$149M
Total Non-Current Liabilities$29M$26M$23M$19M$164M
Total Liabilities$57M$54M$74M$61M$215M
— Equity —
Common Stock$6K$6K$6K$10K$16K
Retained Earnings-$228M-$397M-$633M-$950M-$1.4B
Accumulated OCI-$269K-$571K$0$6K$0
Total Stockholders Equity$368M$252M$91M$630M$972M
Total Liabilities & Equity$426M$306M$165M$691M$1.2B
— Key Metrics —
Total Debt$33M$30M$27M$24M$20M
Net Debt-$168M-$142M-$94M-$411M-$873M
Total Investments$176M$84M$1M$207M$217M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms